Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Abbott Labs Announces CE Mark For Testosterone Test - Quick Facts

RELATED NEWS
Trade ABT now with 

Abbott Laboratories (ABT: Quote) announced CE Marking or Conformite Europeenne for a testosterone assay with improved sensitivity and clinical utility. The company noted that ARCHITECT 2nd Generation Testosterone Assay can accurately measure the wide range of testosterone levels seen in a number of different patient populations and clinical settings.

Testosterone assays play an important role in the diagnosis and management of many medical conditions in men, women, and children.

The company stated that the new assay runs on its fully-automated ARCHITECT family of analyzers and is available in several European countries, Asia Pacific, Latin America, Japan, Africa, Middle East, and India, pending country registration.

The ARCHITECT 2nd Generation Testosterone Assay is a chemiluminescent microparticle immunoassay for the quantitative determination of testosterone in human serum and plasma.

Click here to receive FREE breaking news email alerts for Abbott Laboratories and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
LinkedIn Corp., the world's largest online professional network, said Thursday after the markets closed that it swung to a second quarter loss, hurt by higher costs and expenses even as revenue surged 47%. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue. Kraton Performance Polymers, Inc. (KRA), Wednesday reported second-quarter net income of $11.1 million or $0.33 per share, up from $3.8 million or $0.12 per share last year. Adjusted earnings improved to $0.46 per share from $0.15 per share last year. Revenues for the quarter dropped to $323.8... Organic grocer Whole Foods Market, Inc. said Wednesday after the markets closed that its third quarter profit rose 6.3% from last year, as same-store sales increased 3.9%. The company's quarterly earnings per share also came in above analysts' expectations, but its quarterly sales fell shy of analyst' forecast.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.